华润双鹤(600062.SH)：将在重大疾病、小分子创新药、小核酸药物等方向加快布局

Core Viewpoint - The company is focusing on clinical needs and steadily expanding its research pipeline in key areas such as oncology, antiviral treatments, and ophthalmology, with a commitment to enhancing innovation in drug development [1] Group 1: Drug Development Progress - The company has 15 projects progressing steadily in its innovation pipeline [1] - The modified new drug Panxin®-Mercaptopurine Tablets (Ⅱ) has been approved for production, filling a gap in precision treatment for childhood leukemia in China, achieving a balance between safety and efficacy [1] - The first-class anti-tumor drug DC50292A has received clinical approval from both the National Medical Products Administration and the FDA [1] - The first-class anti-tumor new drug DC05F01 is continuing to enroll participants for its Phase II clinical trial [1] - The 1.1 class biological drug J002 for treating dry eye syndrome has obtained clinical implied approval [1] Group 2: Future Directions - The company plans to accelerate its layout in major diseases, small molecule innovative drugs, and small nucleic acid drugs [1] - There is a continuous emphasis on strengthening independent innovation and cutting-edge technology reserves [1] - The company aims to comprehensively speed up its research and development transformation process [1]